These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12732461)

  • 1. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA.
    Haj HT; Salerno M; Priebe W; Kozlowski H; Garnier-Suillerot A
    Chem Biol Interact; 2003 Jun; 145(3):349-58. PubMed ID: 12732461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of a new bisintercalating anthracycline antibiotic.
    Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
    J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy.
    Robinson H; Priebe W; Chaires JB; Wang AH
    Biochemistry; 1997 Jul; 36(29):8663-70. PubMed ID: 9289011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic.
    Leng F; Priebe W; Chaires JB
    Biochemistry; 1998 Feb; 37(7):1743-53. PubMed ID: 9485299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence selective binding of bis-daunorubicin WP631 to DNA.
    Fox KR; Webster R; Phelps RJ; Fokt I; Priebe W
    Eur J Biochem; 2004 Sep; 271(17):3556-66. PubMed ID: 15317591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new bisintercalating anthracycline with picomolar DNA binding affinity.
    Portugal J; Cashman DJ; Trent JO; Ferrer-Miralles N; Przewloka T; Fokt I; Priebe W; Chaires JB
    J Med Chem; 2005 Dec; 48(26):8209-19. PubMed ID: 16366602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermodynamics of the anthracycline-nuclei interactions in drug-resistant and drug-sensitive K562 cells.
    Tarasiuk J; Garnier-Suillerot A
    Biochem Pharmacol; 1992 Jun; 43(12):2575-80. PubMed ID: 1632816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei.
    Frezard F; Garnier-Suillerot A
    Biochim Biophys Acta; 1990 Nov; 1036(2):121-7. PubMed ID: 2223830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the effects of daunorubicin and WP631 on transcription.
    Portugal J; Martín B; Vaquero A; Ferrer N; Villamarín S; Priebe W
    Curr Med Chem; 2001 Jan; 8(1):1-8. PubMed ID: 11172687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.
    Averbuch SD; Clawson RE; Bachur NR; Felsted RL
    Cancer Chemother Pharmacol; 1986; 16(3):211-7. PubMed ID: 2421935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives.
    Garbesi A; Bonazzi S; Zanella S; Capobianco ML; Giannini G; Arcamone F
    Nucleic Acids Res; 1997 Jun; 25(11):2121-8. PubMed ID: 9153311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3'-hydroxylated analogs.
    Jollès B; Laigle A; Priebe W; Garnier-Suillerot A
    Chem Biol Interact; 1996 Mar; 100(2):165-76. PubMed ID: 8646789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative effects on the formation of intercalation sites.
    Trieb M; Rauch C; Wibowo FR; Wellenzohn B; Liedl KR
    Nucleic Acids Res; 2004; 32(15):4696-703. PubMed ID: 15342790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of a DNA-bisdaunomycin complex.
    Hu GG; Shui X; Leng F; Priebe W; Chaires JB; Williams LD
    Biochemistry; 1997 May; 36(20):5940-6. PubMed ID: 9166763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631.
    Villamarín S; Mansilla S; Ferrer-Miralles N; Priebe W; Portugal J
    Eur J Biochem; 2003 Feb; 270(4):764-70. PubMed ID: 12581216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
    Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI
    Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
    Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
    Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of anthracycline--DNA complexes by circular dichroism.
    Rizzo V; Penco S; Menozzi M; Geroni C; Vigevani A; Arcamone F
    Anticancer Drug Des; 1988 Aug; 3(2):103-15. PubMed ID: 3165639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of the cyano moiety in the crystal structure of N-cyanomethyl-N-(2-methoxyethyl)-daunomycin complexed with d(CGATCG).
    Saminadin P; Dautant A; Mondon M; Langlois D'estaintot B; Courseille C; Précigoux G
    Eur J Biochem; 2000 Jan; 267(2):457-64. PubMed ID: 10632715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.